New prostate cancer radiation aims to cut side effects by using less dose

NCT ID NCT06177093

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing a new way to give radiation for prostate cancer that uses an MRI machine to guide the treatment. The goal is to give a lower dose of radiation to the whole prostate while giving a higher dose only to the main tumor, which may reduce side effects like urinary, bowel, and sexual problems. The study will enroll 20 men with intermediate-risk prostate cancer and follow them for up to 2 years to see if the approach is safe and works well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MR Linac delivered Radiotherapy
What this could lead to
If successful, this approach could reduce urinary, bowel, and sexual side effects from prostate cancer radiotherapy without compromising cancer control.
What could go wrong
This is a very small pilot study with only 20 men, so results may not apply broadly. The lower dose might also be less effective at controlling the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.